Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
ASND Stock Chart & Stats
Day’s Range― - ―
52-Week Range$111.09 - $199.99
Previous CloseN/A
Volume129.18K
Average Volume (3M)515.96K
Market Cap
$11.91B
Enterprise Value$10.78B
Total Cash (Recent Filing)$517.92M
Total Debt (Recent Filing)$847.27M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Nov 13, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding60,970,566
10 Day Avg. Volume475,956
30 Day Avg. Volume515,959
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue34.69
Enterprise Value/Gross Profit40.26
Enterprise Value/Ebitda-63.58
Forecast
1Y Price Target
$247.59Price Target Upside25.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Bulls Say, Bears Say
Bulls Say
Market Growth PotentialThe company has penetrated less than 5% of the market, suggesting ample room for growth in the US market with an estimated 70K-90K patients.
Prescription UptakeA significant increase in U.S. Yorvipath prescriptions suggests a rapid uptake since launch announcement.
Revenue PerformanceYorvipath revenues beat company-compiled consensus by about 33%.
Bears Say
Market CompetitionYorvipath's clinical benefit and strong potential to maintain a favorable market position despite emerging competition are highlighted.
Market ExpectationsThe FDA approval of Skytrofa for adult patients with growth hormone deficiency has been widely expected based on compelling efficacy from the Ph3 study.
Sales PerformanceSales of Skytrofa were reported at €50.7M, which was below consensus estimates of €63.2M/€58.9M, suggesting weaker market performance.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $111.09 and its highest was $199.99 in the past 12 months.
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is $11.91B.
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is Nov 13, 2025 which is in 77 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Aug 07, 2025. The company reported -$0.959 earnings per share for the quarter, beating the consensus estimate of -$1.504 by $0.545.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is -0.31.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 60,970,566 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of -$0.959 in its last earnings report, beating expectations of -$1.504. Following the earnings report the stock price went up 0.599%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Currently, no hedge funds are holding shares in ASND
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$247.59 (25.90% Upside)
$247.59 (25.90% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 862.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.96%
12-Months-Change
Fundamentals
Return on Equity
357.68%
Trailing 12-Months
Asset Growth
57.13%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma is a biopharmaceutical company focused on transforming the lives of patients through innovative therapies. The company operates primarily in the sectors of endocrinology, oncology, and rare diseases, leveraging its proprietary TransCon technology platform to develop a pipeline of product candidates that address unmet medical needs. Ascendis Pharma's core products include TransCon Growth Hormone for growth hormone deficiency and TransCon PTH for hypoparathyroidism, among others, aimed at providing enhanced treatment options for patients.
ASND Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance for Ascendis Pharma with significant revenue growth, successful product launches, and strategic progress in their pipeline. While there are challenges related to currency impacts and patient conversion timelines, these are offset by the momentum in product adoption and regulatory advancements.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$247.59
▲(25.90% Upside)
Technical Analysis
Ownership Overview
―
Insiders
31.93% Mutual Funds
0.21% Other Institutional Investors
66.44% Public Companies and
Individual Investors